MELANOMA

This early-phase trial tests a custom-made RNA vaccine designed to help the immune system recognize and attack tumors in people with advanced melanoma or soft tissue sarcoma whose cancer has worsened despite standard immunotherapy. Up to 18 adults will receive three doses of the …

This study is for adults with advanced solid tumors that have spread or cannot be removed by surgery. It tests a new drug, enzelkitug, given alone or with standard immunotherapy drugs. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors.…

This study tests a new drug called AZD6750, which helps the immune system fight cancer. It is for adults with advanced solid tumors like melanoma, lung cancer, or breast cancer that have not responded to other treatments. The study will check safety, find the best dose, and see i…

This study tests a drug called entrectinib, already approved for some lung and solid tumors, in people with rare cancers that have a specific genetic change (ROS1 fusion). About 30 adults and children with various cancer types (except non-small cell lung cancer) will receive the …

This study tests a combination of two drugs, enfortumab vedotin and pembrolizumab, in people with advanced melanoma that has stopped responding to standard therapies. The goal is to see if this combo can shrink tumors or slow the disease. About 60 adults with unresectable stage I…

This study looks at whether adding a prebiotic-rich diet to standard immunotherapy (ipilimumab and nivolumab) before surgery is feasible and helpful for people with melanoma. About 35 adults with stage III or IV melanoma will take part. The goal is to see if participants can stic…

This study tests an experimental drug called TRK-950, alone or with another cancer drug (nivolumab), in people with advanced solid tumors or melanoma that has not responded to standard treatments. The goal is to check safety and see if the drug can shrink tumors. About 49 adults …

This early-phase study tests a new oral drug, PF-07799933, in people aged 16 and older with advanced solid tumors (like melanoma, lung, or colon cancer) that have a specific BRAF gene change and have stopped responding to standard treatments. The drug is given alone or combined w…

This study tests a drug called tegavivint in children, teens, and young adults whose solid tumors have come back or stopped responding to treatment. The goal is to find the safest dose and see if it can shrink tumors by blocking a key growth signal inside cancer cells. About 147 …

This study tests a new two-drug combination (fianlimab and cemiplimab) against an approved treatment (Opdualag) for people with advanced melanoma that cannot be removed by surgery or has spread. About 560 adults who have not had prior therapy for this stage of melanoma will parti…

This early-stage study tests a new treatment for children and young adults (up to age 21) with solid tumors that have come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack a protein c…

This study tests whether adding a fecal microbiota transplant called LND101 to standard immunotherapy can lower the chance of advanced melanoma growing or spreading. About 128 people with stage IV or unresectable melanoma will receive either immunotherapy alone or immunotherapy p…

This early-stage trial tests a new treatment called T3011, given as a shot directly into tumors, for people with advanced solid tumors that have stopped responding to standard care. Some participants will also receive the immunotherapy drug pembrolizumab (Keytruda) through an IV.…

This study tests whether adding the drug pembrolizumab to a treatment that uses a patient's own immune cells (called TIL therapy) can shrink tumors in people with advanced melanoma. About 53 adults aged 18-72 with skin melanoma that has spread will take part. Participants receive…

This early-phase study tests an experimental oral drug called NST-628 in adults with advanced solid tumors that have specific genetic changes in the MAPK pathway. The main goals are to check the drug's safety, find the right dose, and see if it shrinks tumors. About 230 participa…

This study tests an experimental drug called N17350 for adults with advanced solid tumors that have not responded to standard treatments. The drug is injected directly into tumor lesions every two weeks for up to 12 weeks. Researchers aim to find the safest dose, check for side e…

This study tests a new cancer medicine (PF-07799544) taken as a pill, alone or with another drug, in adults with advanced solid tumors that have a specific gene change (BRAF V600). The goal is to see if the combination is safe and can shrink or control tumors. About 124 people wi…

This study tests whether combining two drugs, axitinib and ipilimumab, can shrink tumors in people with advanced melanoma that has stopped responding to standard immunotherapy. About 25 adults with unresectable melanoma will receive the combination. The main goal is to see how ma…

This study tests a new combination of immune cells—CAR T cells, cytotoxic T lymphocytes (CTLs), and dendritic cell (DC) vaccines—to fight advanced melanoma that has spread or come back after standard treatment. About 30 adults aged 18 to 75 with confirmed melanoma antigens will r…

This study is for people with stage III melanoma that has spread to just one lymph node. Researchers want to see if removing only that cancerous node (instead of many nodes) can stop the cancer from coming back in that same spot. The trial will also look at side effects like swel…

This study tests whether adding low-dose radiation to the liver can help immunotherapy work better for people with non-small cell lung cancer or melanoma that has spread to the liver. About 21 adults will receive standard immunotherapy plus low-dose liver radiation. The goal is t…

This study tests a new drug, BMS-986340, alone or with other treatments, in people with advanced solid tumors like lung, colon, or cervical cancer. The goal is to find safe doses and see if it helps control the disease. About 1,100 participants will be enrolled.

This study tests a new drug called GI-101, alone or with other drugs (pembrolizumab or lenvatinib), in people with advanced solid tumors that have spread. The goal is to see if it is safe and can shrink or control the tumors. About 317 adults with certain cancers like lung, kidne…

This study tests whether adding a precise form of radiation (stereotactic radiosurgery) to standard drug therapy can better control brain metastases in patients with melanoma or non-small cell lung cancer. About 180 participants with newly diagnosed, untreated brain metastases wi…

This program provides early access to two experimental drugs, botensilimab and balstilimab, for people with serious or life-threatening cancers like colorectal, pancreatic, lung, liver, melanoma, sarcoma, ovarian, or prostate cancer. It is for patients who have tried all standard…

This early-phase study tests two drugs, ulixertinib and palbociclib, together in people with advanced solid tumors, including pancreatic cancer and certain melanomas. The main goal is to find the safest dose and check for side effects. About 45 adults whose cancer has not respond…

This study tests a personalized cancer vaccine made from tumor cells grown in a lab. The cells are modified to boost the immune system, then killed and injected into the patient. The goal is to help the body fight cancer and extend survival in people with metastatic melanoma, bre…

This study tests a combination of two drugs (atezolizumab and BDB001) plus radiation therapy in people with advanced solid tumors, including pancreatic, lung, and breast cancers. The goal is to see if this triple therapy can control the disease for at least 24 weeks. About 247 ad…

This program offers ulixertinib, an experimental drug, to adults with advanced solid tumors that have specific gene mutations (MAPK pathway). Participants must have tried all other treatments or not responded well. The goal is to control the cancer, not cure it, and patients may …

This early-stage trial tests a new treatment called IDOV-Immune, which uses a specially designed virus to infect and kill cancer cells while also boosting the immune system. It is for adults with advanced solid tumors (like colorectal, lung, or breast cancer) that have not respon…

This study tests a new drug called NUC-7738, given alone or with another drug (pembrolizumab), in people with advanced solid tumors or lymphoma that haven't responded to other treatments. The goal is to find the safest dose and see if it can shrink tumors or slow cancer growth. A…

This study tests an experimental drug, REGN10597, alone or with another drug (cemiplimab) in people with advanced solid tumors like melanoma and kidney cancer. The goal is to see if the treatment is safe and can shrink tumors. About 240 adults whose cancer has worsened after stan…

This study tests an oral drug called NEO212 in people with specific brain tumors (astrocytoma, glioblastoma) or cancers that have spread to the brain. The goal is to find the safest dose and see if it helps control tumor growth. About 134 adults will take NEO212 alone or with sta…

This study looks at how well the drug T-DXd works for adults with advanced HER2-positive solid tumors who have already tried other treatments and have no good alternatives. About 100 people will take T-DXd as part of their regular care, and researchers will track tumor shrinkage …

This study tests atezolizumab, a drug already approved for some cancers, in people with rare cancers that have high tumor mutational burden (TMB) or microsatellite instability (MSI). About 30 adults and children with these genetic changes will receive the drug to see if it shrink…

This study tests whether adding the arthritis drug sarilumab to a standard immunotherapy combo can reduce side effects and work better for people with advanced melanoma that can't be removed by surgery. About 105 adults with stage III or IV melanoma will receive all four drugs to…

This study tests two drugs, vemurafenib and cobimetinib, already approved for melanoma, in adults with rare cancers that have a specific BRAF V600 mutation. The goal is to see if the combination can shrink tumors or stop them from growing for at least 24 weeks. About 30 participa…

This early-stage trial is testing a new drug called BI-1808, alone or with pembrolizumab, in people with advanced cancers (like ovarian cancer, melanoma, or T-cell lymphoma) that have stopped responding to standard treatments. The main goals are to check the drug's safety, find t…

This study tests a new treatment for adults with certain cancers (pancreatic, kidney, breast, melanoma, or ovarian) that have a protein called CD70. Doctors take a sample of your blood, modify your white blood cells in a lab to recognize and attack CD70, and then give them back t…

This study tests a new treatment for people with advanced melanoma that has come back or not responded to standard therapy. The treatment uses specially engineered immune cells (CAR-T cells) that target two proteins, NG2 and DLL3, found on melanoma cells. The goal is to see if th…

This early-phase study tests a new drug, PF-08046054/SGN-PDL1V, alone or with pembrolizumab, in people with advanced solid tumors that have spread or can't be removed. The main goal is to check safety and find the right dose. About 714 participants with cancers like lung, head an…

This study tests an experimental treatment called OBX-115 for people with advanced melanoma or non-small cell lung cancer that has spread or stopped responding to standard therapy. OBX-115 uses a patient's own immune cells (tumor-infiltrating lymphocytes) that are modified in the…

This study tests a new way to deliver radiation therapy for people with lung cancer, melanoma, or kidney cancer that has started to grow again in a few spots despite treatment. The approach uses a PET scan to find the most active parts of the tumor and delivers a higher radiation…

This phase 2 trial tests a personalized treatment called GC101 TIL for people with advanced melanoma that has not responded to standard therapies. Doctors take immune cells from the patient's own tumor, grow them in a lab, and give them back to fight the cancer. The study will co…

This study tests whether adding lifileucel (a therapy using a patient's own immune cells grown in a lab) to the standard immunotherapy pembrolizumab works better than pembrolizumab alone for people with advanced melanoma that has not been treated yet. About 670 participants will …

This early-stage study tests a new drug, MGC026, in about 250 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check the drug's safety and find the right dose. Participants receive the drug by IV and are monitored for side effe…

This study tests an experimental drug called GV20-0251 in adults with advanced solid tumors (like lung, colon, or head and neck cancers) that have stopped responding to standard treatments. The goal is to see if the drug can shrink tumors or slow their growth. About 350 participa…

This study tests a type of internal radiation called high-dose-rate brachytherapy for people with liver tumors that cannot be surgically removed. The treatment uses a tiny radioactive source placed directly into the tumor to kill cancer cells while sparing nearby healthy organs. …

This study tests whether adding hydroxychloroquine (a malaria drug) to standard immunotherapy (nivolumab with or without ipilimumab) can help shrink tumors in people with advanced melanoma that has spread. About 94 participants will receive the combination to find the safest dose…

This study is testing a drug called pembrolizumab in children aged 6 months to 18 years with advanced melanoma, solid tumors, or lymphomas that have spread, come back, or not responded to treatment. The drug helps the immune system fight cancer. The goal is to see if it can shrin…

This early-phase study tests whether fecal microbiota transplantation (FMT) can safely treat severe diarrhea or colon inflammation caused by immune-checkpoint inhibitor drugs in people with genitourinary and other cancers. About 40 participants will receive FMT to see if it reduc…

This study tests a combination of two experimental drugs, HX009 and IN10018, with or without standard chemotherapy, in people with advanced solid tumors like bile duct cancer and melanoma. The goal is to find the best dose and see if the combination shrinks tumors. About 124 adul…

This early-phase study tests a modified herpes virus (RP1) injected into melanoma tumors to see if it can reduce the chance of cancer spreading to nearby lymph nodes. About 25 adults with thick or high-risk melanoma will receive the treatment before standard lymph node removal. T…

This study tests an experimental drug called patritumab deruxtecan in people with advanced solid tumors that have spread or cannot be removed. The drug targets a protein called HER3 found on many cancer cells. About 740 adults with various cancers like lung, breast, or melanoma w…

This early-stage trial tests the safety of a new drug called GV20-0251 in people with advanced solid tumors (like liver, lung, or pancreatic cancer) that have stopped responding to standard therapies. About 10 participants will receive the drug at one of two dose levels. The goal…

This study tests whether adding a low-dose chemotherapy drug (cyclophosphamide) to an immunotherapy (pembrolizumab) can shrink tumors in people with advanced melanoma that no longer responds to checkpoint inhibitors alone. About 14 adults with stage III or IV melanoma will receiv…

This study tests whether giving two immunotherapy drugs (ipilimumab and nivolumab) before surgery can help people with melanoma that came back after prior treatment. About 25 adults with high-risk, removable melanoma will receive the drugs, then have standard surgery and follow-u…

This early-phase study tests a personalized cell therapy for people with advanced solid tumors (sarcoma, lung cancer, or melanoma) that have not responded to first-line treatment. The therapy uses the patient's own immune cells, which are genetically modified to recognize and att…

This study offers continued access to dabrafenib and/or trametinib for up to 100 patients with cancers like melanoma or lung cancer who were already benefiting from these drugs in a prior Novartis or GSK trial. The main goal is to monitor long-term safety and side effects over ti…

This study tests a treatment called electrochemotherapy for people with tumors in organs like the liver or pancreas that cannot be removed by surgery. The treatment uses short electric pulses to help the chemotherapy drug bleomycin enter cancer cells more effectively. About 24 ad…

This study tests a combination of three immunotherapy drugs (relatlimab, nivolumab, and ipilimumab) in 60 people with melanoma that has spread to the brain. The goal is to see if the drugs can shrink or stabilize brain tumors for at least six months. Participants must have at lea…

This study tests whether adding common diabetes drugs (metformin or rosiglitazone) to standard immunotherapy (anti-PD-1) can improve treatment for advanced solid tumors like melanoma, lung, liver, and stomach cancers. About 72 adults will receive immunotherapy alone or with one o…

This early-phase trial tests a treatment that uses your own immune cells (tumor-infiltrating lymphocytes) to attack advanced uveal melanoma or certain sarcomas. About 30 adults with these cancers will have their immune cells collected from a tumor, grown in a lab, and then infuse…

This study tests whether adding the drug tarlatamab to standard radiation therapy is safe for people with cancers that have a protein called DLL3, including melanoma, lung cancer, and glioblastoma. About 30 adults with advanced or returning cancers will receive both treatments, a…

This study tests a new drug called HLX17 to see if it works like the approved drug Keytruda in people who have had surgery for lung cancer, melanoma, or kidney cancer. About 174 adults will receive either HLX17 or Keytruda, and researchers will compare how the drugs move through …

This study tests whether giving immunotherapy before and after surgery helps people with advanced melanoma. About 90 adults with stage III or IV melanoma will receive treatment based on their tumor markers. The goal is to see if this approach leads to better tumor shrinkage and l…

This early study tests an experimental drug called VSV-02 in 6 adults with advanced solid tumors (like melanoma, breast, or lung cancer) who have run out of standard options. The drug is given both through a vein and directly into the tumor to see if it can shrink or control the …

This early-stage study tests a new drug, BI 3810944, in adults with advanced solid tumours or melanoma who have run out of treatment options. The goal is to find safe doses and see if the drug can shrink tumours. Participants receive the drug every three weeks for up to two years…

This study tests an experimental oral drug called 7HP349 (Alintegimod) taken with standard immunotherapy drugs (ipilimumab and nivolumab) for people with advanced solid tumors like melanoma, lung, kidney, or liver cancer who have already tried other treatments. The goal is to see…

This early-phase study tests a new drug called DXC014 in up to 150 people with advanced solid tumors, including small cell lung cancer, melanoma, and prostate cancer. The main goal is to check safety and find the best dose. Participants must have tried other treatments and be in …

This study looks at whether giving radiation to the lymph node area, along with standard immunotherapy, can lower the chance of melanoma coming back in patients whose sentinel lymph node biopsy showed high-risk features. About 168 adults with melanoma that has spread to one lymph…

This study tests a new way to treat advanced melanoma by boosting a patient's own immune cells (TIL) with a molecule called CD40L. After removing a tumor, the cells are grown in a lab, strengthened, and given back to the patient along with chemotherapy and short-term IL-2. The go…

This early-stage study tests an oral probiotic (R-5780) taken alongside a standard immunotherapy drug (PD-1 inhibitor) in adults with advanced solid tumors like melanoma. The main goal is to check safety and side effects. About 33 participants will be enrolled to see if this comb…

This early-stage study tests a new treatment called MQ710, made from a modified virus, for people with advanced solid tumors that have not responded to standard therapies. The treatment is injected directly into tumors, either alone or with the immunotherapy drug pembrolizumab. T…

This study tests a new type of PET scan that targets a protein called LRRC15, found on many cancers. Researchers will scan 26 people—both healthy volunteers and patients with cancers like pancreatic, breast, lung, or brain tumors—to see if the scan can better find and stage the d…

This study tests if a special ultrasound using a contrast agent (Sonazoid) can find the first lymph node where cancer might spread, called the sentinel node. It involves 91 adults with melanoma, breast cancer, or head & neck cancer who are already scheduled for surgery. If succes…

This study tests if doing a lymphovenous bypass before lymph node surgery can prevent lymphedema (arm swelling) in people with advanced breast cancer or melanoma. The bypass creates a new path for lymph fluid to drain away from the arm. Researchers will compare swelling rates in …

This study is testing whether a virtual mind-body program called Integrative Medicine at Home (IM@Home) can improve fatigue and other symptoms in adults with head and neck, thoracic, gynecologic, or melanoma cancers who are receiving treatments like chemotherapy or radiation. Abo…

This study tests a telemedicine program called FOCUS for people with advanced cancer. The program uses counseling techniques to help with sleep problems, worry, fatigue, and mood. Researchers want to see if using the app improves symptoms and quality of life for 120 patients, esp…

This study compares giving cancer treatment at home versus in a clinic for 27 adults with various cancers in the Florida Panhandle. The goal is to see if patients prefer home treatment and if it is safe. Participants will receive their usual cancer drugs either at home or in the …

This study looks at whether people with certain cancers prefer getting their immune therapy as a quick shot under the skin (subcutaneous) or as a longer IV drip. About 880 adults who are already eligible for nivolumab or pembrolizumab will try both ways and report which they like…

This study tests a new radiation technique called lattice radiation therapy (LRT) against standard radiation for people with tumors that have spread to soft tissues. The goal is to see if LRT shrinks tumors better and helps the immune system fight cancer. About 26 adults with var…

This study is testing a program called MyCarePulse and ASCENT to help cancer patients overcome food-related challenges. About 100 adults recently diagnosed with certain cancers will either receive the program or standard care. The goal is to see if the program improves food secur…

This study aims to collect blood samples from 2,500 people with cancer or at high risk for cancer. The samples will be stored and used in future research to better understand how cancer grows and responds to treatment. No direct treatment is given; the goal is to create a resourc…

This study looks at how electrochemotherapy—a treatment that uses electric pulses to help chemotherapy drugs enter cancer cells—changes the environment around melanoma tumors that have spread to the skin. Researchers will collect tissue samples from 150 adults before and after tr…

This study collects and stores tissue and blood samples from 3,000 people with melanoma. Researchers will analyze the samples to find genetic changes linked to the cancer's start and growth. The goal is to help doctors choose the best treatment for each patient and speed up test …

This study collects blood, tissue, urine, and saliva from 7,000 people who have or had cancer to look for tiny bits of cancer DNA left after treatment. The goal is to find cancer early if it comes back and to help doctors decide on next steps. Participants must have had or be pla…

This study is testing a new tool that predicts whether a patient's melanoma will respond to immunotherapy. Researchers will collect tumor, blood, and stool samples from 1,000 participants with skin cancers like melanoma. The goal is to see how accurate the prediction model is in …

This study follows 270 women under 40 who have had melanoma surgery and are now taking newer drugs (targeted therapy or immunotherapy) to prevent the cancer from coming back. The goal is to measure how these drugs affect the ovaries and a woman's ability to have children later. N…

This study is testing whether an artificial intelligence (AI) tool can help match cancer patients with clinical trials they might be eligible for. Researchers will enroll up to 50,000 people with various types of cancer to see if the AI increases trial enrollment and to identify …

This study interviews 75 people with advanced cancers (like breast, lung, or leukemia) who have been taking daily targeted pills for months or years. Researchers want to hear about their real-life experiences, challenges, and needs. No new treatment is being tested — the goal is …

This study is tracking 2000 adults with newly diagnosed breast, colorectal, lung, melanoma, or lymphoma cancer who are getting chemotherapy or immunotherapy. Researchers want to see if using cannabis or cannabinoids helps with symptoms like pain, nausea, or fatigue, and whether i…

This study uses a short questionnaire to learn how the COVID-19 pandemic impacted the quality of life, mental health, finances, and social connections of people with melanoma. Researchers will also look at what factors, like social support, helped patients cope. About 1,152 parti…

This study aims to collect and analyze tumor samples from 10,000 adults with advanced solid cancers (like breast, lung, or colon cancer). The goal is to create a large database linking each person's cancer gene profile to their health records. This information will help doctors m…

This study follows 350 people with stage III-IV melanoma during their first two years after diagnosis to understand how they feel and function. Researchers will also test whether a type of talk therapy called cognitive behavioral therapy (CBT-C) can help reduce cancer-related str…

This study tests a digital program called mySmartSkin to help melanoma survivors do better skin self-exams. About 385 people who had melanoma surgery in the past 3 months to 5 years will use the app and report how thoroughly they check their skin. The goal is to see if the app he…

This study aims to test an educational tool designed for people with melanoma who also have an autoimmune disease, such as rheumatoid arthritis or Crohn's disease. Researchers want to see if the tool helps patients and their doctors make better decisions about using immune checkp…

This study looks at how a standard melanoma immunotherapy (anti-PD1) changes the appearance and biology of atypical moles in 30 people with stage IIB-IIIC melanoma. Participants will have their moles photographed and analyzed before and after treatment. The goal is to learn more …

This study looks at how genes and the environment affect the risk of melanoma, a serious skin cancer. Researchers will enroll up to 3,000 people with a personal or family history of melanoma. Participants fill out questionnaires, give blood or cheek cell samples, and may have ski…

This study is testing whether a mobile app called Vigilant can help monitor side effects in 100 people with skin cancer or melanoma who are starting a specific type of immunotherapy. Participants will use the app to report any symptoms they experience, and researchers will track …

This study looks at whether combining a special PET/CT scan with a blood test for tumor DNA can help doctors know early on if immunotherapy is working for people with advanced melanoma. About 24 adults with stage III or IV melanoma will have scans and blood draws before and 3-4 w…

This study collects blood and tissue samples from 2000 people—some with cancer, some without—to build a reference set for evaluating new blood tests that aim to detect multiple cancers early. Researchers will use these samples to measure how accurate the tests are at telling canc…

This study collects blood and leftover tissue samples from 9,600 adults with different types of cancer, such as breast, lung, and pancreatic cancer. Researchers will use these samples to improve tests that look for tiny bits of cancer DNA in the blood. The goal is to better detec…

This study tests whether people with advanced solid tumors can stick to a diet low in methionine, a protein building block. Researchers want to see if this diet is safe and changes methionine levels in the blood. About 25 adults will follow the diet while receiving their usual ca…

This study looks at how well first-line immunotherapy works for people with metastatic melanoma in Slovenia. Researchers will track tumor shrinkage and survival, and analyze blood, stool, and body fluids to find markers that predict who benefits most. The goal is to better tailor…

This study watches patients who already received at least one dose of Replimune's oncolytic immunotherapy (RPx) for up to 5 years to see if any delayed side effects appear. It does not give any new treatment—just regular check-ins. About 50 adults with melanoma, advanced solid tu…

This study is creating a huge collection of medical information and biological samples from adults with or at risk for many types of cancer, as well as healthy volunteers. The goal is to help researchers better understand what causes cancer and how to prevent, detect, and treat i…

This study is testing a blood test that looks for tiny bits of cancer DNA (called ctDNA) to find if a tumor is coming back earlier than usual scans. Researchers will follow 100 people with various cancers, plus healthy volunteers, to see if the test helps predict cancer growth or…

This study collects blood and tumor samples from 1,000 people with melanoma and healthy volunteers. Researchers want to learn more about what causes melanoma and how tumors behave. The stored samples may help future studies find better ways to diagnose or treat this skin cancer.

This study tracks how certain melanoma treatments affect fertility in women (ages 18-37) and men (ages 18-45). Researchers measure hormone levels and sperm quality before, right after, and one year after treatment ends. The goal is to understand the impact on future family-buildi…

This study analyzes tumor samples from 12,000 cancer patients to find gene changes (mutations). The goal is to match each person with a personalized treatment or clinical trial that targets their specific cancer type. Researchers will also build a database of mutations to help fu…

This study looks at the genetic makeup of skin growths (including melanoma) in children and teens under 19. Researchers will analyze tissue samples already stored or newly collected to learn more about these rare childhood cancers. No new treatments are given—the goal is simply t…

This study looks at whether watching a video before genetic testing helps people with certain cancers (like breast, ovarian, or prostate) better understand their risk. About 1,020 adults who have had cancer and speak English or Spanish will take part. The goal is to see if this v…

This study looks at whether urolithin A, a natural compound, can improve the immune response in people with solid tumors like lung cancer or melanoma who are starting immunotherapy. About 45 participants will be randomly assigned to take urolithin A or a placebo alongside their s…

This study is collecting tumor samples from 300 people with high-risk blood or solid cancers, including leukemia, multiple myeloma, and pancreatic cancer. Researchers will use advanced lab tests to create a detailed profile of each tumor. The goal is to see if this information ca…

This study screens adults with cancers like melanoma, lung, or bladder cancer to see if they qualify for experimental treatments. These treatments take white blood cells from the patient's tumor or blood, grow them in a lab, and return them to fight the cancer. The goal is to fin…

This study looks at whether giving young adults (ages 18-39) with cancer the option to choose how they report their symptoms and well-being leads to better data. About 400 participants will be randomly assigned to either a fixed set of questions or a choice of questions. The goal…